Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: The Company develops, manufactures, and markets specialized products, primarily apparatus and scientific instruments, for life science research (LSRT segment) and regenerative medicine (RMD segment). Operations are global, with significant exposure to foreign currencies (British pound, Euro).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenues | $26,312 | $26,300 |
| Gross Profit | $12,369 | $12,782 |
| Gross Margin | 47.0% | 48.6% |
| Operating Income | $1,950 | $2,976 |
| Net Income | $1,676 | $2,221 |
| Diluted EPS | $0.06 | $0.07 |
| Cash from Operations | $1,144 | $3,108 |
| Cash and Equivalents (Ending) | $20,088 | $17,043 |
| Long-Term Debt | $17,107 | $18,009 |
Material Changes vs. Prior Period
- Revenue: Flat year-over-year ($26.3M vs. $26.3M). Organic revenue in core businesses decreased 2.1% excluding the impact of the Coulbourn Instruments acquisition and foreign currency fluctuations. A weakened U.S. dollar added $0.2M to revenue.
- Profitability: Net income declined 25% to $1.7M. Operating income dropped 34% to $2.0M, driven by a decrease in gross margin (47.0% vs. 48.6%) due to sales mix changes and increased operating expenses.
- Expenses: Sales and marketing expenses rose 9.7% due to spending in both LSRT and RMD segments. General and administrative expenses increased 2.2%, primarily due to the Coulbourn acquisition.
- Cash Flow: Operating cash flow decreased significantly to $1.1M from $3.1M, primarily due to changes in working capital (specifically a $1.8M increase in inventory and a $1.5M decrease in accrued expenses).
- Tax Benefit: The Company recorded a discrete tax benefit of approximately $0.5M due to the expiration of the statute of limitations on uncertain tax positions, resulting in a near-zero effective tax rate for the quarter.
Guidance, Outlook, and Risks
- Outlook: Management expects the softness in Q1 (attributed to U.S. federal funding delays and the Japan tragedy) to be temporary, noting strengthened orders in April. The strategy focuses on organic growth, tuck-under acquisitions, and operational improvements.
- Regenerative Medicine (RMD): The Company is investing in RMD tools (bioreactors and injectors). Management is reviewing strategic alternatives to maximize value in the RMD business, including potential partnerships or investments.
- Liquidity: The Company has $20.1M in cash and $2.9M available under its $20M revolving credit facility. Management believes current resources are sufficient for operations for 12 months and beyond, though additional capital may be needed for significant acquisitions.
- Risks: Key risks include foreign currency fluctuations, reliance on government research funding (NIH), integration of acquisitions, and the ability to obtain regulatory approvals for new RMD products.
Investor Verification Checklist
- Inventory Build: Verify the rationale for the $1.8M increase in inventory and its impact on future working capital needs.
- RMD Strategy: Monitor announcements regarding the strategic review of the Regenerative Medical Device business and potential partnerships.
- Debt Covenants: Confirm continued compliance with the $20M credit facility covenants, particularly given the reduction in operating cash flow.
- Organic Growth: Assess whether the Q1 revenue decline in core businesses (excluding acquisitions and FX) is a trend or a temporary anomaly.
- Tax Position: Note that the Q1 net income was boosted by a one-time tax benefit; future effective tax rates may differ significantly.